539 related articles for article (PubMed ID: 15896665)
21. Assessment of a vesicular stomatitis virus-based vaccine by use of the mouse model of Ebola virus hemorrhagic fever.
Jones SM; Stroher U; Fernando L; Qiu X; Alimonti J; Melito P; Bray M; Klenk HD; Feldmann H
J Infect Dis; 2007 Nov; 196 Suppl 2():S404-12. PubMed ID: 17940977
[TBL] [Abstract][Full Text] [Related]
22. Pathogenesis of viral hemorrhagic fever.
Bray M
Curr Opin Immunol; 2005 Aug; 17(4):399-403. PubMed ID: 15955687
[TBL] [Abstract][Full Text] [Related]
23. Pathogenesis of Marburg hemorrhagic fever in cynomolgus macaques.
Hensley LE; Alves DA; Geisbert JB; Fritz EA; Reed C; Larsen T; Geisbert TW
J Infect Dis; 2011 Nov; 204 Suppl 3():S1021-31. PubMed ID: 21987738
[TBL] [Abstract][Full Text] [Related]
24. Reverse genetic generation of recombinant Zaire Ebola viruses containing disrupted IRF-3 inhibitory domains results in attenuated virus growth in vitro and higher levels of IRF-3 activation without inhibiting viral transcription or replication.
Hartman AL; Dover JE; Towner JS; Nichol ST
J Virol; 2006 Jul; 80(13):6430-40. PubMed ID: 16775331
[TBL] [Abstract][Full Text] [Related]
25. Cytokine and chemokine expression in humans infected with Sudan Ebola virus.
Hutchinson KL; Rollin PE
J Infect Dis; 2007 Nov; 196 Suppl 2():S357-63. PubMed ID: 17940971
[TBL] [Abstract][Full Text] [Related]
26. Proinflammatory response during Ebola virus infection of primate models: possible involvement of the tumor necrosis factor receptor superfamily.
Hensley LE; Young HA; Jahrling PB; Geisbert TW
Immunol Lett; 2002 Mar; 80(3):169-79. PubMed ID: 11803049
[TBL] [Abstract][Full Text] [Related]
27. Mechanisms underlying coagulation abnormalities in ebola hemorrhagic fever: overexpression of tissue factor in primate monocytes/macrophages is a key event.
Geisbert TW; Young HA; Jahrling PB; Davis KJ; Kagan E; Hensley LE
J Infect Dis; 2003 Dec; 188(11):1618-29. PubMed ID: 14639531
[TBL] [Abstract][Full Text] [Related]
28. Identification of the Ebola virus glycoprotein as the main viral determinant of vascular cell cytotoxicity and injury.
Yang ZY; Duckers HJ; Sullivan NJ; Sanchez A; Nabel EG; Nabel GJ
Nat Med; 2000 Aug; 6(8):886-9. PubMed ID: 10932225
[TBL] [Abstract][Full Text] [Related]
29. Ebola virus: new insights into disease aetiopathology and possible therapeutic interventions.
Geisbert TW; Hensley LE
Expert Rev Mol Med; 2004 Sep; 6(20):1-24. PubMed ID: 15383160
[TBL] [Abstract][Full Text] [Related]
30. Histopathological and immunohistochemical studies of lesions associated with Ebola virus in a naturally infected chimpanzee.
Wyers M; Formenty P; Cherel Y; Guigand L; Fernandez B; Boesch C; Le Guenno B
J Infect Dis; 1999 Feb; 179 Suppl 1():S54-9. PubMed ID: 9988165
[TBL] [Abstract][Full Text] [Related]
31. Immunopathogenesis of severe acute respiratory disease in Zaire ebolavirus-infected pigs.
Nfon CK; Leung A; Smith G; Embury-Hyatt C; Kobinger G; Weingartl HM
PLoS One; 2013; 8(4):e61904. PubMed ID: 23626748
[TBL] [Abstract][Full Text] [Related]
32. Shed GP of Ebola virus triggers immune activation and increased vascular permeability.
Escudero-Pérez B; Volchkova VA; Dolnik O; Lawrence P; Volchkov VE
PLoS Pathog; 2014 Nov; 10(11):e1004509. PubMed ID: 25412102
[TBL] [Abstract][Full Text] [Related]
33. VP24 is a molecular determinant of Ebola virus virulence in guinea pigs.
Mateo M; Carbonnelle C; Reynard O; Kolesnikova L; Nemirov K; Page A; Volchkova VA; Volchkov VE
J Infect Dis; 2011 Nov; 204 Suppl 3():S1011-20. PubMed ID: 21987737
[TBL] [Abstract][Full Text] [Related]
34. Current knowledge on lower virulence of Reston Ebola virus (in French: Connaissances actuelles sur la moindre virulence du virus Ebola Reston).
Morikawa S; Saijo M; Kurane I
Comp Immunol Microbiol Infect Dis; 2007 Sep; 30(5-6):391-8. PubMed ID: 17610952
[TBL] [Abstract][Full Text] [Related]
35. Successful treatment of ebola virus-infected cynomolgus macaques with monoclonal antibodies.
Qiu X; Audet J; Wong G; Pillet S; Bello A; Cabral T; Strong JE; Plummer F; Corbett CR; Alimonti JB; Kobinger GP
Sci Transl Med; 2012 Jun; 4(138):138ra81. PubMed ID: 22700957
[TBL] [Abstract][Full Text] [Related]
36. Ebola virus: unravelling pathogenesis to combat a deadly disease.
Hoenen T; Groseth A; Falzarano D; Feldmann H
Trends Mol Med; 2006 May; 12(5):206-15. PubMed ID: 16616875
[TBL] [Abstract][Full Text] [Related]
37. Development of treatment strategies to combat Ebola and Marburg viruses.
Paragas J; Geisbert TW
Expert Rev Anti Infect Ther; 2006 Feb; 4(1):67-76. PubMed ID: 16441210
[TBL] [Abstract][Full Text] [Related]
38. Lymphocyte death in a mouse model of Ebola virus infection.
Bradfute SB; Braun DR; Shamblin JD; Geisbert JB; Paragas J; Garrison A; Hensley LE; Geisbert TW
J Infect Dis; 2007 Nov; 196 Suppl 2():S296-304. PubMed ID: 17940964
[TBL] [Abstract][Full Text] [Related]
39. Towards a vaccine against Ebola virus.
Geisbert TW; Jahrling PB
Expert Rev Vaccines; 2003 Dec; 2(6):777-89. PubMed ID: 14711361
[TBL] [Abstract][Full Text] [Related]
40. Therapeutics of Ebola hemorrhagic fever: whole-genome transcriptional analysis of successful disease mitigation.
Yen JY; Garamszegi S; Geisbert JB; Rubins KH; Geisbert TW; Honko A; Xia Y; Connor JH; Hensley LE
J Infect Dis; 2011 Nov; 204 Suppl 3():S1043-52. PubMed ID: 21987740
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
